Developmental work continues on EchoGen, an ultrasound contrast agent from Sonus Pharmaceuticals. In conjunction with ultrasound scanner vendor Hewlett-Packard, Sonus has completed an image optimization trial that has determined the scanner control
Developmental work continues on EchoGen, an ultrasound contrast agent from Sonus Pharmaceuticals. In conjunction with ultrasound scanner vendor Hewlett-Packard, Sonus has completed an image optimization trial that has determined the scanner control parameters required to provide the highest level of cardiac image enhancement using its EchoGen ultrasound contrast agent.
The trial, which was conducted at the VA Medical Center in Dallas, consisted of 18 patients who were given EchoGen and then scanned using an HP Sonos 2500 LE echocardiography scanner. Sonos 2500 LE was designed for use in harmonic imaging studies with ultrasound contrast (SCAN 7/3/96).
In addition to determining optimal system settings, researchers found that on average, EchoGen demonstrated a persistence of at least five minutes, according to Sonus, which is headquartered in Bothell, WA.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.